Inventor · disambiguated record
Annette Feussner
Also filed as: FEUSSNER ANNETTE
18 granted patents·7 pending applications·121 citations·filing 1999–2019
93Inventor score
Files withAVENTIS BEHRING GMBH9CSL BEHRING GMBH8ZLB BEHRING GMBH4DELTA BIOTECHNOLOGY LTD1SCHULTE STEFAN1
Top patents by PatentIndex Score
25 records- 0188US7550567B2Fibrinogen purificationCSL BEHRING GMBH·Filed 2005·Granted Jun 23, 2009·21 cites·21 claims
- 0285US6677440B1Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or a mixture of both proteins by means of ion-exchange chromatographyAVENTIS BEHRING GMBH·Filed 2000·Granted Jan 13, 2004·22 cites·17 claims
- 0383US6831167B2Mutants of the factor VII-activating protease and detection methods using specific antibodiesAVENTIS BEHRING GMBH·Filed 2001·Granted Dec 14, 2004·9 cites·6 claims
- 0479US7153679B2Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosisAVENTIS BEHRING GMBH·Filed 2003·Granted Dec 26, 2006·9 cites·20 claims
- 0579US6670455B1Process for the preparation in pure form of the protease activating blood clotting VII, its proenzyme or a mixture of both proteins by means of affinity chromatographyAVENTIS BEHRING GMBH·Filed 2000·Granted Dec 30, 2003·12 cites·13 claims
- 0673US7202065B2Stabilized liquid preparation of the protease which activates blood coagulation factor VII, or of its proenzymeZLB BEHRING GMBH·Filed 2002·Granted Apr 10, 2007·9 cites·25 claims
- 0771US6911334B2Protease for activating clotting factor VIIZLB BEHRING GMBH·Filed 2002·Granted Jun 28, 2005·4 cites·10 claims
- 0871US6573056B2Process for purifying factor VII and activated factor VIIAVENTIS BEHRING GMBH·Filed 2001·Granted Jun 3, 2003·3 cites·12 claims
- 0971US6528299B1Protease for activating clotting factor VIIAVENTIS BEHRING GMBH·Filed 1999·Granted Mar 4, 2003·22 cites·11 claims
- 1069US7892842B2Procedure for the determination of the activity of the protease which activates factor VII from protein solutionsCSL BEHRING GMBH·Filed 2008·Granted Feb 22, 2011·0 cites·19 claims
- 1165US7863009B2Mutants of the factor VII-activating protease and detection methods using specific antibodiesCSL BEHRING GMBH·Filed 2008·Granted Jan 4, 2011·0 cites·8 claims
- 1264US7879803B2Methods of treatment involving the protease for activating clotting factor VIICSL BEHRING GMBH·Filed 2007·Granted Feb 1, 2011·0 cites·13 claims
- 1363US7442514B2Mutants of the factor VII-activating protease and detection methods using specific antibodiesCSL BEHRING GMBH·Filed 2004·Granted Oct 28, 2008·0 cites·19 claims
- 1463US2020338123A1Methods to reduce adverse events caused by pharmaceutical preparations comprising plasma derived proteinsCSL BEHRING GMBH·Filed 2019·Application pending·0 cites
- 1557US2005202002A1Protease for activating clotting factor VIIZLB BEHRING GMBH·Filed 2005·Application pending·0 cites
- 1656US7803569B2Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis and methods of detecting FSAP and FSAP mutationsCSL BEHRING GMBH·Filed 2006·Granted Sep 28, 2010·0 cites·20 claims
- 1755US6835817B2Monoclonal antibody which is specific for activated coagulation factor VII, and its useZLB BEHRING GMBH·Filed 2002·Granted Dec 28, 2004·0 cites·8 claims
- 1852US6906183B2Process for the separation of glycosylated and nonglycosylated proteinsDELTA BIOTECHNOLOGY LTD·Filed 1999·Granted Jun 14, 2005·8 cites·11 claims
- 1950US2004186277A1Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or a mixture of both proteins by means of ion-exchange chromatographyAVENTIS BEHRING GMBH·Filed 2003·Application pending·0 cites
- 2050US2004063187A1Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or a mixture of both proteins by means of chromatographyAVENTIS BEHRING GMBH·Filed 2003·Application pending·0 cites
- 2147US2003124622A1Procedure for the determination of the activity of the protease which activates factor VII from protein solutionsFiled 2002·Application pending·0 cites
- 2244US2015150911A2Methods to reduce adverse events caused by pharmaceutical preparations comprising plasma derived proteinsSCHULTE STEFAN·Filed 2012·Application pending·0 cites
- 2343US7829095B2Inhibitory monoclonal antibody against blood clotting factor VII-activating proteaseCSL BEHRING GMBH·Filed 2003·Granted Nov 9, 2010·0 cites·2 claims
- 2442US2004161810A1Monoclonal antibodies specific for latent antithrombin III and the use thereofFiled 2003·Application pending·0 cites
- 2540US6479245B1Monoclonal antibody which is specific for activated coagulation factor VII, and its useAVENTIS BEHRING GMBH·Filed 1999·Granted Nov 12, 2002·2 cites·9 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →